199 related articles for article (PubMed ID: 33032086)
1. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
Eggermont AMM; Bellomo D; Arias-Mejias SM; Quattrocchi E; Sominidi-Damodaran S; Bridges AG; Lehman JS; Hieken TJ; Jakub JW; Murphree DH; Pittelkow MR; Sluzevich JC; Cappel MA; Bagaria SP; Perniciaro C; Tjien-Fooh FJ; Rentroia-Pacheco B; Wever R; van Vliet MH; Dwarkasing J; Meves A
Eur J Cancer; 2020 Nov; 140():11-18. PubMed ID: 33032086
[TBL] [Abstract][Full Text] [Related]
2. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Amaral T; Sinnberg T; Chatziioannou E; Niessner H; Leiter U; Keim U; Forschner A; Dwarkasing J; Tjien-Fooh F; Wever R; Flatz L; Eggermont A; Forchhammer S
Eur J Cancer; 2023 Mar; 182():155-162. PubMed ID: 36739215
[TBL] [Abstract][Full Text] [Related]
3. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.
Johansson I; Tempel D; Dwarkasing JT; Rentroia-Pacheco B; Mattsson J; Ny L; Olofsson Bagge R
Eur J Surg Oncol; 2022 Feb; 48(2):320-325. PubMed ID: 34794843
[TBL] [Abstract][Full Text] [Related]
4. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
[TBL] [Abstract][Full Text] [Related]
5. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.
Hsueh EC; DeBloom JR; Lee JH; Sussman JJ; Covington KR; Caruso HG; Quick AP; Cook RW; Slingluff CL; McMasters KM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036233
[TBL] [Abstract][Full Text] [Related]
7. Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse.
Mulder EEAP; Johansson I; Grünhagen DJ; Tempel D; Rentroia-Pacheco B; Dwarkasing JT; Verver D; Mooyaart AL; van der Veldt AAM; Wakkee M; Nijsten TEC; Verhoef C; Mattsson J; Ny L; Hollestein LM; Olofsson Bagge R
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740520
[TBL] [Abstract][Full Text] [Related]
8. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
10. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
[TBL] [Abstract][Full Text] [Related]
11. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
Gastman BR; Gerami P; Kurley SJ; Cook RW; Leachman S; Vetto JT
J Am Acad Dermatol; 2019 Jan; 80(1):149-157.e4. PubMed ID: 30081113
[TBL] [Abstract][Full Text] [Related]
12. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy.
Arnot SP; Han G; Fortino J; Han D; Fowler G; Vetto JT
Am J Surg; 2021 Jun; 221(6):1195-1199. PubMed ID: 33773750
[TBL] [Abstract][Full Text] [Related]
13. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
Mulder EEAP; Dwarkasing JT; Tempel D; van der Spek A; Bosman L; Verver D; Mooyaart AL; van der Veldt AAM; Verhoef C; Nijsten TEC; Grunhagen DJ; Hollestein LM
Br J Dermatol; 2021 May; 184(5):944-951. PubMed ID: 32844403
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients.
Gambichler T; Tsagoudis K; Kiecker F; Reinhold U; Stockfleth E; Hamscho R; Egberts F; Hauschild A; Amaral T; Garbe C
Eur J Cancer; 2021 Jan; 143():11-18. PubMed ID: 33278769
[TBL] [Abstract][Full Text] [Related]
15. The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma.
Jarell A; Skenderis B; Dillon LD; Dillon K; Martin B; Quick AP; Siegel JJ; Rackley BB; Cook RW
Future Oncol; 2021 Dec; 17(36):5023-5031. PubMed ID: 34587770
[TBL] [Abstract][Full Text] [Related]
16. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.
Marchetti MA; Coit DG; Dusza SW; Yu A; McLean L; Hu Y; Nanda JK; Matsoukas K; Mancebo SE; Bartlett EK
JAMA Dermatol; 2020 Sep; 156(9):953-962. PubMed ID: 32745161
[TBL] [Abstract][Full Text] [Related]
17. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
[TBL] [Abstract][Full Text] [Related]
18. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD
Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM
JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma.
Lee RJ; Gremel G; Marshall A; Myers KA; Fisher N; Dunn JA; Dhomen N; Corrie PG; Middleton MR; Lorigan P; Marais R
Ann Oncol; 2018 Feb; 29(2):490-496. PubMed ID: 29112704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]